Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn

Upon acquisition, Angelini Pharma will integrate Catalyst’s portfolio and infrastructure to advance rare disease therapies. Credit: MrWinn / Shutterstock.com.